Second Quarter 2016 Financial Results

IRADIMED CORPORATION Announces Second Quarter 2016 Financial Results

IRADIMED CORPORATION Announces Second Quarter 2016 Financial Results • Revenue grows 29.7% compared to the same quarter last year • Reports second quarter 2016 GAAP diluted EPS of $0.19 and non-GAAP diluted EPS of $0.24 • Increases full year 2016 non-GAAP earnings guidance • Submits patient vital signs monitor 510(k) application to FDA for review Winter Springs, Florida, July 29, 2016 – IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (MRI) procedures, today announced financial results for the three and six months ended June 30, 2016. For the second quarter ended June 30, 2016, the Company reported revenue of $9.9 million, an increase of 29.7% compared to $7.6 million for the second quarter 2015. Gross profit margin was 82.4%, compared to 81.3% for the second quarter 2015. Net income was $2.2 million, an increase of 26.0% compared to $1.8 million for the second quarter 2015 and earnings per diluted share increased 27.5% to $0.19, compared to $0.15 per diluted share for the second quarter 2015. Non-GAAP net income was $2.9 million for the second quarter ended June 30, 2016, an increase of 48.2% over the second quarter 2015. Non-GAAP earnings per diluted share increased 49.9% to $0.24 per diluted share, compared to $0.16 in the second quarter 2015. Free cash flow was $1.1 million, a decrease of 31.0% compared to the second quarter 2015. For the six months ended June 30, 2016, the Company reported revenue of $18.8 million, an increase of 29.0% compared to $14.6 million for the same period in 2015. Gross profit margin was 81.7%, compared to 81.2% for the same period in 2015. Net income was $4.5 million, an increase of 38.5% compared to $3.3 million for the same period in 2015 and earnings per diluted share increased 37.7% to $0.37, compared to $0.27 per diluted share for the same period in 2015. Non-GAAP net income was $5.5 million for the six months ended June 30, 2016, an increase of 51.2% over the same period in 2015. Non-GAAP earnings per diluted share increased 50.3% to $0.45 per diluted share for the six months ended June 30, 2016, compared to $0.30 in the same period in 2015. Cash and cash equivalents decreased by $7.3 million to $12.1 million during the six months ended June 30, 2016. The Company generated $3.8 million of cash from operations and repurchased $10.0 million of its stock during the six months ended June 30, 2016. “I am very pleased with our second quarter financial results. Revenue for the quarter was nearly 30% higher than last year’s quarter and non-GAAP diluted earnings per share increased nearly 50%. Additionally, we are receiving a higher volume of requests for quotes and those quotes are for higher dollar amounts than what we have historically seen. We view quotes as a leading indicator of future orders and feel that the current level of quoting will lead to increased bookings as customer budget years roll over,” said Roger Susi, President and Chief Executive Officer of the Company. “Related to new products, we recently submitted a 510(k) application for our patient vital signs monitor and now wait to hear back from FDA as they review our submission. We remain excited about the launch of this product still scheduled for later this year. We continue to receive positive feedback about the patient monitor and have already received several unsolicited orders from a few of our international distributors. Additionally, earlier in July, we underwent an FDA site inspection and await the final results as to the clearing of the September 2014 warning letter,” said Susi. Financial Guidance For the third quarter 2016 the Company expects revenue of approximately $9.9 million to $10.0 million and non-GAAP diluted earnings per share of $0.23 to $0.24. The Company increased its full year 2016 non-GAAP earnings guidance and now expects non-GAAP diluted earnings per share of $0.91 to $0.93, an increase from the previous guidance of $0.88 to $0.90. Full year revenue guidance was unchanged at $39.0 million to $40.0 million. Use of non-GAAP Financial Measures The Company believes the presentation of non-GAAP net income, free cash flow and infrequent income tax items can be helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with GAAP. We calculate non-GAAP net income as net income excluding stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allow for meaningful comparisons between our operating results from period to period. We calculate free cash flow as net cash provided by operating activities less net cash used in investing activities for purchases of property and equipment. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making acquisitions, strengthening our balance sheet and returning cash to our shareholders via share repurchases. Infrequent tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes. All of our non-GAAP financial measures are important tools for financial and operational decision making and for evaluating our operating results. A reconciliation of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of cash flows. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with U.S. GAAP and are not indicative of net income or cash provided by operating activities. Conference Call IRADIMED has scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time today, July 29, 2016. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering the reservation code 50949035. The conference call will also be available real-time via the internet at www.iradimed.com/enus/investors/index.php and selecting Events & Presentation. A recording of the call will be available on the Company’s website following the completion of the call. About IRADIMED CORPORATION IRADIMED CORPORATION is the only known provider of non-magnetic intravenous (IV) infusion pump systems that are specifically designed to be safe for use during magnetic resonance imaging (MRI) procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency (RF) interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated in order to remain immobile during an MRI scan. MRidium is a trademark of IRADIMED CORPORATION. For more information please visit www.iradimed.com. Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Act of 1995, particularly statements regarding our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. These statements relate to future events or our future financial performance or condition and involve unknown risks, uncertainties and other factors that could cause our actual results, level of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. The risks and uncertainties referred to above include, but are not limited to, risks associated with the Company’s ability to receive clearance of its 510(k) submission, additional actions by or requests from the FDA (including a request to cease domestic distribution of products) and unanticipated costs or delays associated with resolution of these matters; our reliance on a single product; unexpected costs, expenses and diversion of management attention resulting from the FDA warning letter; potential disruptions in our limited supply chain for our products; a reduction in international distribution as we focus on fulfilling orders from our U.S. backlog; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations. Further information on these and other factors that could affect the Company’s financial results is included in filings we make with the Securities and Exchange Commission from time to time. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements. IRADIMED CORPORATION CONDENSED BALANCE SHEETS June 30, 2016 December 31, 2015 (unaudited) ASSETS Current assets: Cash and cash equivalents ..............................................................................$ 12,065,858 $ 19,368,114 Investments ..................................................................................................... 8,081,274 7,602,204 Accounts receivable, net ................................................................................. 5,789,495 3,863,632 Inventory, net .................................................................................................. 2,946,314 2,383,158 Prepaid expenses and other current assets ...................................................... 247,663 320,529 Prepaid income taxes ...................................................................................... 292,793 273,968 Deferred income taxes .................................................................................... 320,587 141,446 Total current assets .................................................................................... 29,743,984 33,953,051 Property and equipment, net ................................................................................. 1,219,672 905,622 Intangible assets, net ............................................................................................ 747,633 193,243 Deferred income taxes .......................................................................................... 498,403 88,398 Other assets .......................................................................................................... 138,970 103,893 Total assets ................................................................................................$ 32,348,662 $ 35,244,207 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable ............................................................................................$ 1,180,810 $ 1,005,460 Accrued payroll and benefits .......................................................................... 1,056,037 1,288,248 Other accrued taxes ......................................................................................... 20,493 30,687 Warranty reserve ............................................................................................. 36,082 34,081 Deferred revenue ............................................................................................. 462,264 529,867 Other current liabilities ................................................................................... 108,317 — Accrued income taxes ..................................................................................... 36,782 — Total current liabilities .............................................................................. 2,900,785 2,888,343 Deferred revenue .................................................................................................. 978,269 422,839 Total liabilities ........................................................................................... 3,879,054 3,311,182 Stockholders’ equity: Common stock ................................................................................................ 1,124 1,118 Additional paid-in capital ............................................................................... 21,283,957 19,332,023 Retained earnings ............................................................................................ 17,168,431 12,655,169 Treasury stock ................................................................................................. (9,969,468) — Accumulated other comprehensive loss .......................................................... (14,436) (55,285) Total stockholders’ equity ......................................................................... 28,469,608 31,933,025 Total liabilities and stockholders’ equity ...................................................$ 32,348,662 $ 35,244,207 IRADIMED CORPORATION CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Revenue ........................................................... $ 9,868,905 $ 7,609,143 $ 18,833,058 $ 14,600,848 Cost of revenue ................................................ 1,739,067 1,422,027 3,444,864 2,750,207 Gross profit ......................................... 8,129,838 6,187,116 15,388,194 11,850,641 Operating expenses: General and administrative ........................ 3,088,205 1,985,269 5,347,927 3,953,287 Sales and marketing ................................... 1,409,758 1,104,682 2,692,807 2,193,378 Research and development ......................... 291,822 403,447 526,157 745,748 Total operating expenses ..................... 4,789,785 3,493,398 8,566,891 6,892,413 Income from operations ...................... 3,340,053 2,693,718 6,821,303 4,958,228 Other (expense) income, net ............................ (4,669) 46,135 27,109 92,951 Income before provision for income taxes .................................................... 3,335,384 2,739,853 6,848,412 5,051,179 Provision for income taxes .............................. 1,104,133 969,282 2,335,150 1,793,113 Net income ...................................................... $ 2,231,251 $ 1,770,571 $ 4,513,262 $ 3,258,066 Net income per share: Basic ................................................... $ 0.21 $ 0.16 $ 0.41 $ 0.30 Diluted ................................................ $ 0.19 $ 0.15 $ 0.37 $ 0.27 Weighted average shares outstanding: Basic ................................................... 10,778,673 10,974,448 10,937,311 10,940,525 Diluted ................................................ 11,966,289 12,107,707 12,138,856 12,068,122 IRADIMED CORPORATION CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Six Months Ended June 30, 2016 2015 Operating activities: Net income .......................................................................................................... $ 4,513,262 $ 3,258,066 Adjustments to reconcile net income to net cash provided by operating activities: Bad debt expense ............................................................................................. 33,548 58,666 Provision for excess and obsolete inventory ................................................... 86,610 42,156 Depreciation and amortization ........................................................................ 122,744 106,264 Excess tax benefit on the exercise of stock options ......................................... (266,094) (162,240) Stock-based compensation .............................................................................. 1,595,589 582,085 Impairment of intangible assets ....................................................................... — 55,433 Loss on maturity of securities ......................................................................... 46,753 — Changes in operating assets and liabilities: Accounts receivable ........................................................................................ (1,959,411) (2,359,135) Inventory ......................................................................................................... (649,766) (124,866) Prepaid expenses and other current assets ....................................................... 53,795 133,004 Other assets ..................................................................................................... (16,006) (17,332) Deferred income taxes ..................................................................................... (614,295) (330,989) Accounts payable ............................................................................................ 175,350 306,116 Accrued payroll and benefits ........................................................................... (232,211) (199,949) Other accrued taxes ......................................................................................... (10,194) (52,785) Warranty reserve ............................................................................................. 2,001 31,255 Deferred revenue ............................................................................................. 487,827 993,558 Other current liabilities .................................................................................... 108,317 — Accrued income taxes, net of prepaid income taxes ....................................... 284,051 420,090 Net cash provided by operating activities ................................................ 3,761,870 2,739,397 Investing activities: Purchases of investments ................................................................................ (2,762,917) — Proceeds from the sale or maturities of investments ....................................... 2,303,092 — Purchases of property and equipment ............................................................. (424,047) (121,415) Capitalized intangible assets ........................................................................... (567,137) (5,904) Net cash used in investing activities ........................................................ (1,451,009) (127,319) Financing activities: Proceeds from stock option exercises ............................................................. 90,257 199,060 Income tax benefits credited to equity ............................................................ 266,094 162,240 Purchases of treasury stock ............................................................................. (9,969,468) — Net cash (used in) provided by financing activities ................................. (9,613,117) 361,300 Net (decrease) increase in cash and cash equivalents ............................................. (7,302,256) 2,973,378 Cash and cash equivalents, beginning of period ..................................................... 19,368,114 9,454,150 Cash and cash equivalents, end of period ............................................................... $ 12,065,858 $ 12,427,528 IRADIMED CORPORATION RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (UNAUDITED) Non-GAAP Net Income and Diluted EPS Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net income............................................................ $ 2,231,251 $ 1,770,571 $ 4,513,262 $ 3,258,066 Excluding: Stock-based compensation expense, net of taxes.................................................................. 663,050 182,926 937,863 348,181 Non-GAAP net income................................. $ 2,894,301 $ 1,953,497 $ 5,451,125 $ 3,606,247 Weighted-average shares outstanding – diluted ... 11,966,289 12,107,707 12,138,856 12,068,122 Non-GAAP net income per share – diluted ......... $ 0.24 $ 0.16 $ 0.45 $ 0.30 Free Cash Flow Three Months Ended June 30, 2016 Net cash provided by operating activities............................................................. $ 1,330,017 Less: Purchases of property and equipment ............................................................... 224,709 Free cash flow ............................................................................................... $ 1,105,308 Media Contact: Chris Scott Chief Financial Officer IRADIMED CORPORATION (407) 677-8022 InvestorRelations@iradimed.com

Kevin Jirka